- Home
- NDLS vs XLO Comparison
NDLS vs XLO Comparison
Compare NDLS & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- XLO
- Stock Information
- Founded
- NDLS 1995
- XLO 2016
- Country
- NDLS United States
- XLO United States
- Employees
- NDLS N/A
- XLO N/A
- Industry
- NDLS Restaurants
- XLO Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- XLO Health Care
- Exchange
- NDLS Nasdaq
- XLO Nasdaq
- Market Cap
- NDLS 43.1M
- XLO 37.9M
- IPO Year
- NDLS 2013
- XLO 2021
- Fundamental
- Price
- NDLS $0.89
- XLO $0.75
- Analyst Decision
- NDLS Strong Buy
- XLO Buy
- Analyst Count
- NDLS 2
- XLO 1
- Target Price
- NDLS $3.00
- XLO $4.00
- AVG Volume (30 Days)
- NDLS 87.1K
- XLO 233.1K
- Earning Date
- NDLS 05-07-2025
- XLO 05-13-2025
- Dividend Yield
- NDLS N/A
- XLO N/A
- EPS Growth
- NDLS N/A
- XLO N/A
- EPS
- NDLS N/A
- XLO N/A
- Revenue
- NDLS $493,271,000.00
- XLO $6,344,000.00
- Revenue This Year
- NDLS $4.57
- XLO $668.96
- Revenue Next Year
- NDLS $1.29
- XLO $14.49
- P/E Ratio
- NDLS N/A
- XLO N/A
- Revenue Growth
- NDLS N/A
- XLO N/A
- 52 Week Low
- NDLS $0.55
- XLO $0.62
- 52 Week High
- NDLS $2.36
- XLO $1.70
- Technical
- Relative Strength Index (RSI)
- NDLS 36.36
- XLO 50.38
- Support Level
- NDLS $0.89
- XLO $0.63
- Resistance Level
- NDLS $0.99
- XLO $0.80
- Average True Range (ATR)
- NDLS 0.10
- XLO 0.06
- MACD
- NDLS -0.01
- XLO 0.01
- Stochastic Oscillator
- NDLS 12.74
- XLO 72.71
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).